US equities |
NVDA $236.86 ▲+1.24% SPCX $164.70 ▲+3.61% MU $1,064.84 ▼-0.93% TSLA $378.84 ▲+2.23% MSFT $526.02 ▲+1.64% INTC $116.86 ▼-2.07% SNDK $1,721.61 ▲+0.09% AMD $629.19 ▼-0.74%
FinancialContent

Articles published by ALX Oncology

< Previous 1 2 3 Next >
News headline image
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Appoints Allison Dillon as Chief Business Officer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Pricing of Public Offering
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Proposed Public Offering
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Realigns Executive Leadership Team
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces September Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
News headline image
ALX Oncology Appoints Scott Garland to its Board of Directors
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
< Previous 1 2 3 Next >